Phase 1 · Palo Alto, CA
Phase 1 clinical trials in Palo Alto, CA
23 recruiting studies have a site in Palo Alto.
23 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Xencor, Inc.
- Location
- Palo Alto, CA + 27 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
BioCryst Pharmaceuticals
- Location
- Palo Alto, CA + 4 other US sites
- Eligibility basics
- Ages 12–65
- RecruitingHealthy volunteersPhase 1/Phase 2
FACE Phase II (a Stage II Trial)
Stanford University
- Location
- Palo Alto, CA
- Eligibility basics
- Ages 60–89
- RecruitingHealthy volunteersPhase 1
Imaging Synapses With [11C] UCB-J in the Human Brain
Davidzon, Guido, M.D.
- Location
- Palo Alto, CA + 1 other US site
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
CogT pSOPT Intervention Study
Stanford University
- Location
- Palo Alto, CA
- Eligibility basics
- Ages 60+
- RecruitingPhase 1
Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)
Restem, LLC.
- Location
- Palo Alto, CA
- Eligibility basics
- Ages 15+
- RecruitingPhase 1
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Kite, A Gilead Company
- Location
- Palo Alto, CA + 4 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Autolus Limited
- Location
- Palo Alto, CA
- Eligibility basics
- Ages 18–60
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Palo Alto, CA + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 1
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I…
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Location
- Palo Alto, CA + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Eli Lilly and Company
- Location
- Palo Alto, CA + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Insmed Gene Therapy LLC
- Location
- Palo Alto, CA + 6 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 1/Phase 2
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
NaviFUS Corporation
- Location
- Palo Alto, CA + 2 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
Sarepta Therapeutics, Inc.
- Location
- Palo Alto, CA + 10 other US sites
- Eligibility basics
- Ages 2+ · Men only
- RecruitingPhase 1/Phase 2
Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)
Elpida Therapeutics SPC
- Location
- Palo Alto, CA
- Eligibility basics
- Ages 3–20
- RecruitingPhase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Astellas Institute for Regenerative Medicine
- Location
- Palo Alto, CA + 12 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 1
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
Biogen
- Location
- Palo Alto, CA + 11 other US sites
- Eligibility basics
- Ages 3+
- RecruitingPhase 1/Phase 2
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
- Location
- Palo Alto, CA + 6 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1/Phase 2
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
Kamau Therapeutics
- Location
- Palo Alto, CA + 5 other US sites
- Eligibility basics
- Ages 12–50
- RecruitingPhase 1/Phase 2
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
ModernaTX, Inc.
- Location
- Palo Alto, CA + 5 other US sites
- Eligibility basics
- Ages 1+
- RecruitingPhase 1/Phase 2
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
Neurona Therapeutics
- Location
- Palo Alto, CA + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1/Phase 2
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
ModernaTX, Inc.
- Location
- Palo Alto, CA + 2 other US sites
- Eligibility basics
- Ages 1+
- RecruitingPhase 1/Phase 2
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
Luxa Biotechnology, LLC
- Location
- Palo Alto, CA + 2 other US sites
- Eligibility basics
- Ages 55+
Who these studies look for
Phase 1 studies often have narrow eligibility: specific age and weight ranges, no recent participation in another study, no nicotine, and limits on medications. Some Phase 1 studies recruit patients rather than healthy volunteers, so check each listing.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.